PMOS (Formerly PCOS) and GLP-1 Medications: What to Know
By Anne Wilfong, RDN, LD, CEDS | Wilfong Nutrition LLC | Austin, Texas
If you have PMOS (formerly, and still commonly, known as PCOS), you have probably noticed GLP-1 medications coming up more and more, whether from your provider, your group chats, or your feed. Ozempic, Wegovy, Mounjaro, and Zepbound are being talked about constantly, and a lot of that conversation is aimed at women with PMOS specifically. It is a genuinely fast-moving area, and also one where the noise far outpaces the clear, grounded information. Here is an evidence-based look at where things actually stand, from a weight-neutral dietetics practice in Austin, Texas.
A quick note on the name: in May 2026, an international consensus renamed polycystic ovary syndrome to PMOS (polyendocrine metabolic ovarian syndrome), reflecting that this is a whole-body hormonal and metabolic condition. We use PMOS here, but everything applies to what you may know as PCOS.
Why GLP-1 medications like Ozempic and Wegovy keep coming up with PMOS
The connection is not random. PMOS and GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, intersect at one central feature: insulin resistance. A large share of people with PMOS have some degree of insulin resistance, meaning the body has to work harder to keep blood sugar steady. GLP-1 medications act directly on the systems that regulate blood sugar, appetite, and insulin, which is why they were originally developed for type 2 diabetes, and why they overlap with the metabolic side of PMOS. That overlap is the reason the two topics have become so intertwined.
It is worth being precise about the regulatory picture, because a lot of online content is not. GLP-1 medications are not FDA approved to treat PMOS. They are approved for several other uses, including type 2 diabetes, chronic weight management, and certain cardiovascular, kidney, and sleep apnea indications, but, at the time of this blog post, PMOS is not among them. When they are used for someone with PMOS, that is off-label prescribing, which is legal and a decision made between a patient and their prescriber, but it is not the same as an approved PMOS treatment. Knowing that difference can help you have a clearer conversation with your provider.
What the research actually shows
The honest summary is: promising but incomplete.
Several studies and meta-analyses have found that in women with PMOS, GLP-1 medications can improve markers tied to the condition, things like insulin sensitivity, certain metabolic measures, and in some studies androgen levels. Some research also points to improvements in menstrual regularity, though that finding is less consistent. Those are meaningful signals, and for some people the changes have been significant.
But there is a lot we still do not know. Most studies so far have been small and short-term, though larger trials are now underway. One ongoing trial, RESTORE, is following women and girls with PMOS to see whether semaglutide can help restore ovulation and improve fertility, and early reports are promising. Even so, results like these are still preliminary, and a lot remains uncertain. Researchers also have not fully untangled why improvements happen: whether the benefits come from the medication acting on PMOS directly, from the downstream effects of metabolic change, or from some combination of the two. That distinction matters, and broader trials covering the full metabolic picture, not just fertility, are still needed. And notably, the research consistently shows that weight and metabolic benefits tend to return toward baseline when the medication is stopped, which raises real questions about long-term use that do not have clean answers yet.
So the accurate framing is not "GLP-1s treat PMOS." It is closer to: GLP-1 medications show early promise for some of the metabolic features many people with PMOS deal with, though the research is still developing.
A note on how this gets talked about
Here is where our weight-neutral approach shapes things. A lot of the GLP-1-and-PMOS conversation collapses into weight, the assumption that the goal is weight loss and that everything else follows. We start from how you are actually doing: your energy, your blood sugar, your labs, how you feel in your body day to day. PMOS is a whole-body metabolic and hormonal condition, and those are the things we focus on and support.
Where nutrition fits in, on or off a GLP-1
Nutrition has a real role here, whatever you and your prescriber decide about medication.
For anyone with PMOS, nutrition support centers on the things that genuinely affect how you feel: supporting steady blood sugar through balanced meals, eating in a way that sustains your energy, and doing it without the restriction and food rules that so often get attached to a PMOS diagnosis. There is no single "PMOS diet," and the rigid ones tend to backfire. For more on this, see our blog post nutrition for PMOS.
If you are on a GLP-1, those same fundamentals still apply, with some added considerations on top. These medications can reduce appetite, and getting what your body needs from less food takes a bit more intention. With a smaller appetite, getting enough protein, staying hydrated, and maintaining nutrient density become especially important, because reduced intake can quietly lead to gaps. This is also a population already prone to certain nutrient shortfalls. None of this requires forcing volume you cannot comfortably eat; it is about being intentional with what you can. We cover this more fully in our guide to eating on a GLP-1 blog post.
A few things tend to matter, whether or not you are on a medication, not as rules, but as gentle starting points:
Pairing carbohydrates with protein, fat, or fiber. This tends to support steadier blood sugar and energy than eating carbohydrates on their own, which matters for many people with PMOS. Eating regularly through the day. Long gaps followed by overcorrecting can leave energy and blood sugar bouncing around. A rhythm that fits your life usually feels better than skipping and catching up. Keeping protein and fiber accessible. Especially if appetite is reduced, having easy, appealing sources on hand makes it simpler to meet your needs without forcing large meals. These are flexible starting points, not a prescription, and what works looks different for everyone. That individual piece is a lot of what we help with, in Austin and via telehealth across Texas.
A weight-neutral, eating-disorder-informed lens matters here
One reason we approach this carefully: PMOS, weight, and food can be an emotionally loaded combination, and many people with PMOS arrive carrying years of weight-focused messaging and a complicated relationship with eating. Appetite-suppressing medications add another layer to that.
PMOS is associated with a higher likelihood of disordered eating, and the experience of years of weight-focused advice can leave a real mark on how someone relates to food. GLP-1 medications work in part by reducing appetite and hunger cues, and for someone with a history of restriction or an eating disorder, or who is vulnerable to one, that effect can be complicated. Eating very little can start to feel normal or even encouraged, and the internal signals that help guide eating can become harder to read. None of this means a medication is wrong for any given person, that is a decision for you and your care team, but it is a reason to have support in place, especially if food, eating, or body image have been hard for you in the past.
If any of that resonates, you do not have to navigate it alone, and it is worth bringing into the conversation with people who can help. As a practice that includes a Certified Eating Disorder Specialist, we pay close attention to that whole picture, not just the metabolic numbers.
The bottom line
GLP-1 medications and PMOS are genuinely connected through insulin resistance, and the early research is promising for some of PMOS's metabolic features. But the science is still young, and these medications are not an FDA approved PMOS treatment. Whatever you and your prescriber decide about medication, nutrition support still has a real role, and it works best when it is health-centered, evidence-based, and free of judgment.
If you are navigating PMOS, with or without a GLP-1 medication, and want nutrition support that takes the whole picture seriously, we would love to help. The simplest next step is to reach out to see if we are a good fit. We see clients via telehealth across Texas and in person in Austin, and we are in network with several major insurers, so we can help you check your benefits before your first visit.
Frequently asked questions
Are GLP-1 medications approved to treat PMOS or PCOS? No. GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are FDA approved for type 2 diabetes, chronic weight management, and certain cardiovascular, kidney, and sleep apnea indications, but not for PMOS. They are sometimes prescribed off-label for people with PMOS, which is a decision between a patient and their prescriber.
Why are GLP-1 medications connected to PMOS at all? The link is insulin resistance, which many people with PMOS have. GLP-1 medications act on blood sugar, insulin, and appetite regulation, so they overlap with some of the metabolic features of PMOS.
Do I need to change how I eat on a GLP-1 if I have PMOS? Because these medications can reduce appetite, getting what your body needs from less food takes a bit more intention. Protein, hydration, and nutrient density become especially important. A dietitian can help you do this in a way that fits a smaller appetite, without rigid rules.
